C4 Therapeutics

C4 Therapeutics has been committed to the research and development of drugs for treating cancer and other serious diseases, with the vision of becoming a leader in the field of protein degradation one day. In terms of cancer treatment, the company is accelerating the development of cancer protein degraders using the Degronimid technology platform exclusively licensed from Dana-Farber Cancer Institute at Harvard University. Compared to tumor vaccines that merely target and inhibit the expression of cancer proteins, Degronimid technology cleverly activates the body's existing harmful protein disposal system — the "ubiquitin-proteasome system (UPS)." This means that when facing the threat of cancer proteins, not only can it target and block the expression of cancer proteins, but it can also trigger the human body’s UPS system to directly dissolve cancer cell proteins, effectively "destroying" them.The small molecules developed on the company’s technology platform, named Degronimid, can bind to target proteins on one hand, and on the other hand, bind to proteins within the ubiquitin-proteasome system (UPS) inside cells, prompting the UPS system to tag the target proteins with ubiquitin. Proteins tagged with ubiquitin are eventually degraded by the proteasome. This targeted protein degradation system can address various types of proteins and even degrade many "undruggable" protein targets. As a new disease treatment modality, it has drawn significant attention from the industry.